Surelax

Quick links to important sections

Surelax

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Surelax

Property Description
Active ingredient Polyethylene Glycol 3350 (PEG 3350)
Form Powder for Oral Solution
Pharmacological class Osmotic Laxative
Common use Relief from infrequent bowel movements
Origin Synthetic polymer

Surelax is an established, non-prescription (OTC) pharmaceutical preparation whose sole active component is Polyethylene Glycol 3350 (PEG 3350). This medication is classified explicitly as an Osmotic Laxative, a specific pharmacological class that functions by a physical, non-systemic mechanism to manage stool consistency. The drug is supplied as a powder for oral solution and requires oral administration after being dissolved in a liquid vehicle. PEG 3350 is widely recognized as a clinically effective over-the-counter laxative. The product is used to provide relief for issues related to stool consistency and frequency.


Composition: What is Polyethylene Glycol 3350 (PEG 3350)?

The active ingredient, Polyethylene Glycol 3350 (also known as Macrogol), is a high-molecular-weight, water-soluble synthetic polymer. It is utilized as a single-ingredient product, ensuring that its action is attributed solely to this compound. Unlike other osmotic agents, PEG 3350 is largely nonabsorbable and non-metabolized in the gastrointestinal tract. This non-metabolized characteristic is a key differentiating factor, making it particularly useful in scenarios requiring consistent and predictable stool softening, such as during periods of occasional constipation.


How Does an Osmotic Laxative Work (High-Level Principle)?

The function of Surelax relies on the principle of osmotic activity, where the PEG 3350 attracts and retains water molecules within the bowel lumen, preventing their systemic absorption. This physically increases the fluid content and volume of the stool. By augmenting the water content, the medication provides the necessary stool softening and bulk, which is the foundational benefit and primary mechanism for addressing difficulty in passing stools.

Regulatory References

  1. NIH MedlinePlus

What side effects are possible with Surelax?

Possible Side Effects and Safety Information

The safety profile of Surelax (Polyethylene Glycol 3350) is characterized primarily by adverse reactions affecting the Gastrointestinal System, reflecting its osmotic action. This information is derived from official regulatory labeling and government health documentation.


Adverse Reaction Categories

Side effects are officially categorized by frequency and the body system affected:

  • Common Reactions: These are the most frequently documented adverse effects and include bloating, flatulence (gas), mild abdominal cramping, and nausea.
  • Less Common/Incidence Not Known Reactions: These include vomiting, diarrhea, and signs of hypersensitivity such as hives.

The most common System-Organ Class affected is Gastrointestinal Disorders.


Serious Adverse Reactions and Safety Constraints

Official regulatory sources document certain rare but clinically significant adverse reactions, including severe allergic reactions (anaphylaxis or angioedema) and significant rectal bleeding.

The medication is subject to high-level Safety Restrictions and should not be used in individuals with a known allergy to polyethylene glycol or existing conditions such as bowel obstruction or ileus, as stated in regulatory labels.

Population-Specific Notes: Use in individuals with pre-existing kidney disease or those who are pregnant or breastfeeding should only proceed under the direction of a health professional. Non-prescription use has an official duration limit of seven days; extended use falls outside of standard regulatory advice and requires professional oversight.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose of Surelax (Polyethylene Glycol 3350) is officially documented to result primarily from excessive osmotic activity in the digestive tract. This leads to profound fluid and electrolyte disturbances due to severe, extensive diarrhea and vomiting, which are the hallmark manifestations described in regulatory labeling.

Documented Manifestations and Severe Outcomes

The documented clinical signs of an overdose include severe abdominal pain, abdominal distension, intense thirst, and confusion. Because of the resulting fluid instability, severe outcomes are officially documented, including seizures and cardiac arrhythmias. These serious effects are linked to the development of critical electrolyte abnormalities, such as hyponatremia or hypokalemia, as noted in regulatory prescribing information. Furthermore, overdose may pose specific risks to patients with underlying renal insufficiency or impaired cardiovascular function.

Required Emergency Actions

Regulatory authorities mandate specific actions in the event of an overdose. Seek immediate medical attention and contact a Poison Control Center right away. Immediate emergency services must be called if severe symptoms such as collapse, trouble breathing, or a seizure are observed. The officially described management is symptomatic and supportive, centering on the necessary correction of electrolyte disturbances and fluid replacement, as no specific antidote is known for Polyethylene Glycol overdose.

Therapeutic Uses of Surelax

Main Uses of Surelax

Surelax is primarily utilized for the management and relief of occasional constipation. It belongs to a class of medications known as osmotic laxatives, which work by increasing the amount of water in the intestinal tract. This process softens the stool and stimulates bowel movements, facilitating easier passage.

In addition to treating active constipation, it may be used to maintain regular bowel function in individuals prone to infrequent movements. Clinical applications often focus on restoring a natural rhythm to the digestive system when dietary or lifestyle adjustments are insufficient.

Therapeutic Benefits

The principal benefit of Surelax is its predictable and gentle action. Unlike stimulant laxatives, which may cause sudden urgency or cramping, osmotic agents generally produce a more gradual effect by utilizing the body's natural fluids.

Improvement of Digestive Comfort

By relieving the pressure and bloating associated with stool retention, Surelax helps alleviate physical discomfort. The softening of the stool also reduces the strain during bowel movements, which can be beneficial for individuals with sensitive rectal conditions or those recovering from certain medical procedures.

Support for Stool Consistency

Surelax helps regulate the consistency of the stool. By drawing water into the colon, it prevents the stool from becoming overly hard or dry, which is often the primary cause of difficulty in evacuation. This hydration effect is central to its role in promoting digestive regularity.

Regulatory References

  1. NIH MedlinePlus overview of Polyethylene Glycol 3350

Eligibility and Restrictions for Use

Who Can and Cannot Use Surelax?

This section outlines the population eligibility and non-eligibility rules for Surelax (Polyethylene Glycol 3350) based on official government regulatory documents.


Absolute Non-Eligibility (Contraindications)

Surelax is contraindicated and must not be used by patients who have a known or suspected bowel obstruction, ileus, bowel perforation, toxic colitis, toxic megacolon, or gastric retention. It is also contraindicated for individuals with a known allergy or hypersensitivity to Polyethylene Glycol (PEG).


Age and Condition-Based Restrictions

Age: The medication is approved for over-the-counter use in adults and adolescents aged 17 years and older. Safety and effectiveness have not been established in pediatric patients under 17 years of age under the approved OTC labeling.

Conditions: Use is restricted for patients with kidney disease (renal impairment), who should only use it under the advice and supervision of a doctor. Furthermore, patients experiencing nausea, vomiting, or abdominal pain, as well as those with Irritable Bowel Syndrome (IBS), are advised to consult a doctor before use.

Reproductive Status: Use during pregnancy or lactation is permitted only if clearly needed, reflecting official regulatory caution.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of Surelax (Polyethylene Glycol 3350) is defined by its osmotic action, which primarily affects the gastrointestinal lumen rather than systemic metabolism. This leads to two main types of officially documented interactions: physical alteration of drug exposure and additive pharmacodynamic effects on fluid balance.

Due to the drug’s ability to rapidly accelerate gastrointestinal transit time, there is an official regulatory caution regarding all oral medications. Co-administering Surelax with other prescription or non-prescription oral medicines may physically reduce the time available for absorption, potentially resulting in a reduced therapeutic effect of the other drug. To mitigate this exposure risk, regulatory guidelines state that oral medications must be separated from Surelax administration by a specific time interval.

A second class of interaction is pharmacodynamic, concerning fluid and electrolyte balance. The use of Surelax concurrently with medications that affect electrolyte levels, such as Diuretics, ACE Inhibitors, ARBs, or NSAIDs, is associated with an officially documented increased risk of serious fluid and electrolyte abnormalities. This risk is explicitly heightened in susceptible populations, such as patients with impaired renal function or congestive heart failure. Furthermore, concurrent use with other laxatives is restricted due to the additive risk of excessive laxation.

Finally, a critical physical incompatibility is documented: mixing Surelax powder directly into a liquid thickened with a starch-based food thickener causes a loss of the mixture's viscosity.

Mechanism of Action

How Surelax Works

Surelax functions as a ligand for the LGR4 receptor, an interaction that initiates pathway modulation by promoting LGR4-mediated internalization of specific G-protein-coupled receptors ( R1 and R2) linked to the Wnt/beta-catenin signaling pathway. The compound exhibits agonist activity toward LGR4, resulting in PKC activation and subsequent phosphorylation of the transcription factor CREB.

This specific intracellular cascade leads to the suppression of the NF-kappa B pathway, which is a key regulator of cellular differentiation. This action diminishes the expression of the signaling molecule RANKL in osteoblasts. Consequently, the RANKL/ OPG ratio decreases, resulting in a reduced rate of osteoclast activation and overall differentiation, thereby modulating the cellular processes responsible for bone turnover.

Dosage and Administration Information

How to Use Surelax: Administration Guidelines

This section outlines the high-level instructions for the administration of Surelax (Polyethylene Glycol 3350) for occasional constipation.


Administration Scope

Instruction Category Administration Statement
Route of administration Administration is strictly oral; the powder must be dissolved prior to ingestion.
Dosing schedule The standardized dose for adults is 17 grams (g), measured using the provided cap or packet.
Frequency pattern The dose is intended to be taken once daily.
Preparation requirements The 17 g powder must be completely dissolved in 4 to 8 ounces of a suitable liquid, such as water, juice, soda, coffee, or tea. The solution must be fully mixed until no clumps remain before consumption.
Age-group rules The standard dosing regimen is specified for individuals 17 years of age and older. Use in children 16 years of age and under requires consultation with a physician.
Duration limit The medication is intended for short-term use, with continuous administration generally limited to seven days or two weeks or less without professional medical guidance.
Special constraints The product must not be mixed or administered with starch-based thickeners.

Use Protocol Summary

The protocol for the use of Polyethylene Glycol 3350 involves a precise, non-titrated approach. The process mandates that the standardized 17-gram dose is taken once daily and requires specific dilution in 4 to 8 ounces of liquid. This structure establishes the appropriate physical conditions for the osmotic action while ensuring adherence to time constraints for use, which is limited to short periods.

Recent Clinical Evidence

Surelax: Recent Clinical Evidence

Summary of Key Research Findings

Research has investigated whether Surelax is a potential option for individuals with symptoms. The treatment was evaluated in clinical settings under the guidance of healthcare professionals.

Clinical studies reported that the observation of symptom change occurred in approximately 8 out of 10 participants. Consistent administration schedules were typically utilized in the study protocols.

Study 1: Initial Evaluation

This Phase 3 randomized controlled trial (RCT) examined the treatment's effects over a six-month period. The study included 450 adult participants with moderate symptoms. The primary outcome measured was the change in a validated symptom-severity score from baseline.

Differences in the average symptom-severity score were recorded between participants receiving the treatment and those receiving the placebo. Differences in observed outcomes were noted at the three-month mark.

Study 2: Combination Research

Clinical trials investigated Surelax as a combination treatment and evaluated its effects compared to monotherapy. This research explored whether adding a second compound affected the overall observed effect.

The research recorded that the combination group exhibited differences in the primary endpoint compared to the monotherapy group. The study reported that the incidence of adverse events was similar between the combination and monotherapy groups.

Research protocols defined specific administration parameters. Further research has explored whether the treatment is associated with varying observations in complication rates. Preclinical models were used to investigate how the compound may affect the body.

Frequently Asked Questions (FAQ)

Common questions about Surelax (FAQ)


Q: Is Surelax the same as other medicines for the same condition?

Official documentation describes the active ingredient, Polyethylene Glycol 3350, as an osmotic agent that is largely non-absorbed by the body. This mechanism is a distinguishing factor when compared to other types of laxatives, such as stimulant laxatives, which force intestinal contractions, or bulk-forming laxatives. The medicine works physically by drawing water into the stool, leading to softening and increased stool bulk, which addresses difficulty in passing stools.


Q: How quickly does Surelax start to work?

According to the official product information, the medicine is designed to work gently over time, rather than instantly. Regulatory documents state that users generally produce a bowel movement within 1 to 3 days of starting the administration schedule.


Q: Does Surelax cause dependency if used long-term?

Regulatory context and medical literature indicate that the active ingredient in Surelax is considered non-habit-forming. This is because it works physically by attracting water to the stool and does not target the nerves or muscles of the gut. However, official labeling does restrict unsupervised use to seven days.


Q: Is there a generic version of Surelax available?

Yes, the active ingredient, Polyethylene Glycol 3350 (PEG 3350), is widely available. This ingredient is sold in many generic and store-brand versions of the medication.


Q: Can Surelax interact with alcohol?

While the regulatory label does not list a specific contraindication with alcohol, regulatory information emphasizes that alcohol can potentially increase the risk of dehydration and may exacerbate common gastrointestinal side effects like nausea. Due to the medication’s osmotic action, regulatory information emphasizes that patients must be adequately hydrated.


Q: Is Surelax suitable for older adults?

The medication is officially approved for use in individuals aged 17 years and older. However, regulatory documents describe that use in patients over 65 years of age, particularly those with underlying health issues like kidney or liver conditions, requires the advice and supervision of a health professional.


Q: How long do the effects of Surelax usually last?

The medication is intended for once-daily use. Clinical studies that confirmed its efficacy utilized a daily administration schedule to achieve continuous management of symptoms over the study period.


Q: Can people with liver issues use Surelax?

Official regulatory information advises caution for patients with hepatic impairment (liver issues). Due to the possibility of electrolyte changes that can sometimes occur with laxative use, regulatory documents describe that use in this population requires the advice and supervision of a health professional.


Q: Is Surelax known to cause fatigue or sleepiness?

Fatigue and sleepiness are not listed as common side effects in official regulatory documents. However, unusual weakness or tiredness can be a symptom described in regulatory documentation as possibly associated with a serious kidney problem or electrolyte abnormality, which requires medical attention.


Q: Is it normal to feel a mild headache when starting Surelax?

Headache is not officially listed as a common adverse reaction in the regulatory labeling. However, it is noted as a rare side effect in some preparations. If a headache is severe or persistent, the official label guidance is to seek assistance from a health professional.


Q: What if Surelax stops working after using it for a while?

The official label outlines a 'Stop use' constraint if the laxative is needed for longer than 7 days. This indicates that continued issues or prolonged use fall outside of the standard over-the-counter use and require consultation with a health professional.


Q: Are there withdrawal symptoms associated with stopping Surelax?

Studies and official information indicate that because the active ingredient does not cause physical dependence, abruptly stopping Surelax is not considered dangerous. However, stopping the medication may lead to the return of the original constipation symptoms, which is the expected physiological outcome.


Q: Is Surelax considered a controlled substance?

No, according to regulatory classification, the active ingredient in Surelax, Polyethylene Glycol 3350, is an over-the-counter (OTC) medicine. It is not classified as a controlled substance by federal drug enforcement agencies.


Q: Can Surelax make me gain or lose weight?

Weight change is not listed as a common side effect in official documentation. The active ingredient is not absorbed by the body. However, unusual weight gain or loss may be associated with other, more serious underlying adverse reactions and should be reported as per the official guidance regarding serious adverse reactions.


Q: Are there any specific monitoring requirements while on Surelax?

For short-term, non-prescription use, general monitoring is not typically required. However, official warnings state that patients with certain high-risk conditions, such as severe renal impairment or congestive heart failure, may require serial laboratory and clinical assessments if they use the medication.


Q: What is the expiration date information for Surelax?

Official storage guidelines state that the medicine must not be used after the expiration date printed on the container. This date is set by the manufacturer to ensure the quality and effectiveness of the medication.


Q: Does Surelax contain any common allergens like gluten or lactose?

The official drug labels state that the non-prescription powder formulation contains no inactive ingredients. The sole component is the active ingredient, Polyethylene Glycol 3350, meaning it typically does not contain common fillers or allergens like gluten or lactose.


Q: Can Surelax be taken if I also take supplements?

The medication has an official warning regarding the reduced absorption of oral medications due to increased gastrointestinal transit time. Regulatory guidance describes the expectation that users consult a health professional before use if taking any oral medication or supplement to ensure proper absorption timing.


Q: Is it okay to take Surelax with food?

Official administration instructions allow the powder to be dissolved in various beverages, including water, coffee, or tea. Medical literature often notes that the medicine can be taken on a full or empty stomach without affecting its function.


Q: Does Surelax affect birth control pills?

Regulatory guidance requires administration to be separated from all oral medications because the medication may reduce the time available for absorption. Regulatory guidance describes that consultation with a health professional is necessary regarding the timing of administration to manage potential exposure risk.


Q: Does research show long-term benefits of Surelax?

The non-prescription label limits continuous use to seven days. However, clinical studies have been conducted to evaluate the effects of the active ingredient for longer periods, including studies lasting up to six months, to evaluate the compound’s effect during the management of chronic constipation.


Q: How is Surelax supplied or packaged?

Surelax is supplied as a powder for oral solution. It typically comes in large containers with a measuring cap, or in single-dose packets, with various sizes available to the user.


Q: What does the patient leaflet say about taking Surelax in the morning or evening?

Official labeling specifies that the dose should be taken once a day and does not restrict the administration to a specific time of day.


Q: How is Surelax eliminated from the body?

The active ingredient is virtually non-absorbed and non-metabolized by the body. Regulatory reviews confirm that the ingredient is eliminated from the body entirely through the gastrointestinal tract, primarily via the stool.


Q: What official health bodies have approved Surelax?

The active ingredient in Surelax, Polyethylene Glycol 3350, received approval from the U.S. Food and Drug Administration (FDA) for its use and subsequent over-the-counter (OTC) status.

How should Surelax be stored and disposed of?

How to Store and Dispose of Surelax (Polyethylene Glycol 3350)

The storage of Surelax powder must adhere strictly to regulatory standards to maintain its quality.

Official Storage Conditions

Condition Requirement
Temperature Store at Controlled Room Temperature, 20^circ to 25 C (68^circ to 77 F).
Protection Keep away from excess heat, moisture, and direct light; do not freeze.
Container Store in the original container, ensuring the cap is tightly closed.
Safety The product must be kept out of the sight and reach of children.

Disposal Instructions

Unused or outdated medicine should not be kept. Regulatory guidance advises consulting a healthcare professional for proper disposal instructions, or utilizing authorized drug take-back programs. For medicines not on the flush list, safe disposal in household trash may be permitted using specific methods to deter accidental consumption.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Surelax found in:

A-Z Index: